22.79MMarket Cap
LossP/E TTM
Barinthus Biotherapeutics PLC
Key Figures
0.600Open
0.600High
11.36KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.03%Turnover Ratio
0.557Prev. Close
0.558Low
2.67KTurnover
LossP/E Static
0.34P/B
0.00%Div Yield TTM
-44.70%ROA
2.92052wk High
0.67Volume Ratio
-61.07MNet Profit
40.85MShares
-1.2865EPS TTM
-0.39Beta
-57.52%ROE
0.51252wk Low
7.58%Amplitude
100.00%Gross Margin
22.79MMarket Cap
-1.97Reward/Risk
5.15%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Barinthus Biotherapeutics PLC's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 126 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.50.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Barinthus Biotherapeutics PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Barinthus Biotherapeutics PLC Highlights
StrengthsRisks
Barinthus Biotherapeutics PLC News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Barinthus Biotherapeutics PLC
BRNS
2
Ionis Pharmaceuticals Inc
IONS
25
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Barinthus Biotherapeutics PLC Info
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.
Ticker SymbolBRNS
CompanyBarinthus Biotherapeutics PLC
CEOEnright (William J)
Websitehttps://www.barinthusbio.com/
Shareholders
FAQs
What is the current price of Barinthus Biotherapeutics PLC (BRNS)?
The current price of Barinthus Biotherapeutics PLC (BRNS) is 0.58.
What is the symbol of Barinthus Biotherapeutics PLC?
The ticker symbol of Barinthus Biotherapeutics PLC is BRNS.
What is the 52-week high of Barinthus Biotherapeutics PLC?
The 52-week high of Barinthus Biotherapeutics PLC is 2.92.
What is the 52-week low of Barinthus Biotherapeutics PLC?
The 52-week low of Barinthus Biotherapeutics PLC is 0.51.
What is the market capitalization of Barinthus Biotherapeutics PLC?
The market capitalization of Barinthus Biotherapeutics PLC is 23.51M.
Is Barinthus Biotherapeutics PLC (BRNS) currently rated as Buy, Hold, or Sell?
According to analysts, Barinthus Biotherapeutics PLC (BRNS) has an overall rating of Buy, with a price target of 5.50.
What is the Earnings Per Share (EPS TTM) of Barinthus Biotherapeutics PLC (BRNS)?
The Earnings Per Share (EPS TTM) of Barinthus Biotherapeutics PLC (BRNS) is -1.64.
